SWTX250502C53000
- 0.05
- 0.000.00%
SpringWorks Therapeutics Newsroom
H.C. Wainwright Downgrades SpringWorks Therapeutics(SWTX.US) to Hold Rating, Cuts Target Price to $47
HC Wainwright & Co. Downgrades SpringWorks Therapeutics to Neutral, Lowers Price Target to $47
Hold Rating Issued Amid Concerns Over Merck's Acquisition of SpringWorks Therapeutics
TD Cowen Downgrades SpringWorks Therapeutics(SWTX.US) to Hold Rating, Cuts Target Price to $47
Barclays Maintains SpringWorks Therapeutics(SWTX.US) With Hold Rating, Maintains Target Price $47
Guggenheim Downgrades SpringWorks Therapeutics(SWTX.US) to Hold Rating, Cuts Target Price to $47
Guggenheim Downgrades Springworks Therapeutics to Neutral From Buy, Adjusts Price Target to $47 From $77
TD Cowen Downgrades Springworks Therapeutics to Hold From Buy, Adjusts Price Target to $47 From $66
Express News | SpringWorks Therapeutics Inc : Barclays Cuts to Equal-Weight From Overweight
BofA Keeps Merck at Buy Amid SpringWorks Acquisition
ALERT: Rowley Law PLLC Is Investigating Proposed Acquisition of SpringWorks Therapeutics, Inc.
Analyst Expectations For SpringWorks Therapeutics's Future
SpringWorks Therapeutics Options Spot-On: On April 28th, 98,965 Contracts Were Traded, With 193.81K Open Interest
SpringWorks Therapeutics Analyst Ratings
H.C. Wainwright Maintains SpringWorks Therapeutics(SWTX.US) With Buy Rating, Maintains Target Price $74
Barclays Downgrades SpringWorks Therapeutics(SWTX.US) to Hold Rating, Cuts Target Price to $47
Evercore Downgrades SpringWorks Therapeutics(SWTX.US) to Hold Rating, Cuts Target Price to $47
Merck Germany Buys US Cancer Drugmaker SpringWorks Therapeutics For Around $4 Billion
Merck KGaA's $3.9B SpringWorks Therapeutics Buy Underwhelms -- Market Talk
Barclays Downgrades Springworks Therapeutics to Equalweight From Overweight, Price Target Is $47